Longitude Capital, an investment firm focused on venture growth investments in biotechnology and medical technology, closed its third fund, at $525m in partner commitments.
Longitude Venture Partners III, L.P. (“LVP3″), which exceeded the initial target of $450m, will continue the firm’s strategy of investing in private and public biotechnology and medical technology companies across all stages of development. The new fund is expected to commit an average of $15-25m per investment in approximately 25 companies.
